The JRC has now released a new CRM to aid the fight against beta-thalassemia. This genetic blood disorder reduces the production of hemoglobin, the iron-containing protein in red blood cells carrying ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. When the normal DNA sequence in an individual changes or mutates it can cause ...

The JRC has now released a new CRM to aid the fight against beta-thalassemia. This genetic blood disorder reduces the production of haemoglobin, the iron-containing protein in red blood cells ...

"We have about eight patients that are in the insurance approval process," she said, for gene therapy treatments for beta ...

A company called Bluebird Bio has also developed a gene therapy for people with beta-thalassemia. But this is a challenging process – thalassemia can be caused by one of hundreds of mutations ...

Understanding the genetic underpinnings of each type guides diagnosis and treatment strategies. While alpha Thalassemia is quite uncommon in India but beta thalassemia is pretty common and ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s ...

Raymond James downgraded Editas Medicine ( EDIT, Financials) from outperform to market perform, citing extended development ...